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Abstract 
Since the discovery of the Vascular Endothelial Growth Factor (VEGF) and its leading role in 
the angiogenic process, this has been seen as a promising molecule for promoting neovas-
cularization in the infarcted heart. However, even though several clinical trials were initiated, 
no therapeutic effects were observed, due in part to the short half life of this factor when 
administered directly to the tissue. In this context, drug delivery systems appear to offer a 
promising strategy to overcome limitations in clinical trials of VEGF.  
The aim of this paper is to review the principal drug delivery systems that have been de-
veloped to administer VEGF in cardiovascular disease. Studies published in the last 5 years are 
reviewed and the main features of these systems are explained. The tissue engineering 
concept is introduced as a therapeutic alternative that holds promise for the near future. 
Key words: VEGF, protein delivery, cardiovascular disease, angiogenesis, tissue engineering. 
VEGF 
Discovery 
Vascular Endothelial Growth Factor (VEGF) was 
first  isolated  and  purified  from  the  medium  condi-
tioned  by  bovine  pituitary  folliculo-stellate  cells  by 
Henzel and Ferrara [1]. The newly discovered hepa-
rin-binding  factor  induced  proliferation  of  vascular 
endothelial cells (ECs), showing no effects on corneal 
ECs. This apparent target cell selectivity induced the 
authors to name it “at least provisionally” VEGF [1, 2].  
Some months later Ferrara et al [2] published a 
study in which they demonstrated that VEGF was a 
secreted  protein.  Interestingly,  they  screened  cDNA 
and  isolated  clones  encoding  mature  monomers  of 
121, 165 and 189 amino acids. At the same time Keck 
et al published the purification  of the Vascular Per-
meability Factor [3], identified 5 years before by Sen-
ger et al [4]. Surprisingly, this protein was identical to 
VEGF 189. 
Since that moment a considerable volume of re-
search has been carried out, and it is now known that 
the VEGF 121 isoform is the most diffusible [5]. Two 
mechanisms by which this protein is released into a 
soluble form, namely alternative splicing and prote-
olytic  cleavage,  have  been  described,  in  vivo 
pro-angiogenic activity has been tested, several tyro-
sine kinase VEGF receptors are now known, and an 
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increasing number of molecular studies on VEGF is 
being published [6].  
Biological aspects 
Research focusing on the VEGF family has led to 
the discovery of several members encoded by differ-
ent  genes:  VEGF-A  or  Vascular  Permeability  Factor 
(firstly discovered), B, C, D, E, F and PlGF (Platelet 
Growth Factor)[6, 7]. The most widely studied mem-
ber of the family as far as angiogenesis is concerned 
has been VEGF-A, which  we will refer to as VEGF 
from now on. Different VEGF isoforms from alterna-
tive splicing have been described: VEGF121, 145, 165, 189 and 
206 (number indicates amino acid residues). VEGF121 is 
the freely diffusible form, VEGF145 remains bound to 
cell  surface  and  extracellular  matrix  (ECM)  and 
VEGF189 and VEGF206 are sequestered in the cell sur-
face and ECM [5, 7]. Regarding its different role in 
neovascularization,  briefly,  VEGF121  is  a  mitogenic 
agent  and  a  chemo-attractant  for  endothelial  cells 
(ECs)  during  angiogenesis  and  vasculogenesis. 
VEGF165 is a soluble heparin binding protein, and is 
thus less diffusible than VEGF121, but it exhibits higher 
mitogenic activity. On the other hand VEGF145 induc-
es EC proliferation and angiogenesis in vivo [5].  
From  the  beginning,  researchers  realized  the 
clinical  relevance  of  those  factors  implicated  in  the 
angiogenic process. In fact, the role of anti-angiogenic 
strategies  to  treat  human  cancer  was  proposed  by 
Folkman in 1971, 18 years before VEGF was discov-
ered [8]. On the other hand, pro-angiogenic activity 
also appeared promising as an innovative therapeutic 
approach  in  ischemic  disorders  such  as  myocardial 
ischemia. As VEGF is a secreted protein with EC se-
lective activity it was proposed from the first moment 
as a promising means of regulating angiogenesis.  
VEGF in anti-angiogenic therapy 
Only 4 years were necessary to develop a suc-
cessful  strategy  against  human  cancer  based  on 
VEGF’s  known  involvement  in  vasculogenesis.  The 
proof  of  this  concept  was  carried  out  by  Ferrara’s 
group  [9].  They  administered  an  anti-VEGF  mono-
clonal antibody into nude mice that had been previ-
ously injected with different human tumor cell lines. 
The  treatment  was  successful  in  inhibiting  tumor 
growth. This effect was associated with a diminished 
vessel density in the treated tumors. Studies contin-
ued and in 1997 the first humanized anti-VEGF mon-
oclonal antibody was developed. Approved in 2004 
by the Food and Drug Administration (FDA) for its 
use in patients with previously untreated metastatic 
colorectal  carcinoma,  this  antibody,  named  Bevaci-
zumab  [10],  is  nowadays  used  in  several  diseases, 
namely  breast  cancer  and  macular  degeneration, 
among others.  
Another strategy that has been explored is the 
use of small molecule VEGF receptor tyrosine kinase 
inhibitors.  In  2005  Sorafenib  received  the  FDA  ap-
proval for its use in patients with advanced renal cell 
carcinoma [11]. In 2007 approval was extended for the 
treatment of patients with unresectable hepatocellular 
carcinoma. In the meantime, in 2006 another molecule 
with the same mechanism (Sunitinib malate) was ap-
proved  for  the  treatment  of  advanced  (metastatic) 
renal cell carcinoma and for the treatment of gastro-
intestinal stromal tumor after disease progression, or 
intolerance to the treatment of choice [12].  
VEGF in pro-angiogenic therapy 
To study the role of VEGF in the formation of 
new vasculature it is important to identify different 
processes  in  vessel  formation  [13].  Vasculogenesis 
takes place during mammalian embryo development. 
It consists of the formation of de novo vessels by dif-
ferentiation of angioblasts into ECs. Sprouting during 
angiogenesis is the subsequent process, which ensures 
the expansion of the vessel network. Arteriogenesis 
involves the covering of EC channels by pericytes or 
vascular  smooth  muscle  cells.  Besides  these  steps, 
other mechanisms can occur, such as intussusception 
of pre-existing vessels or recruitment of bone marrow 
derived cells and endothelial progenitor cells that are 
incorporated into the endothelial lining in a process 
known as postnatal vasculogenesis [14]. In all these 
processes, VEGF is present and plays a critical role 
[15].  
In the adult organism, quiescent vessels are con-
stituted by quiescent ECs and pericytes. These sup-
press EC proliferation and release cell survival signals 
like VEGF. When a hypoxic stimulus activates quies-
cent vessels, pericytes are detached from the vessel 
wall. Matrix metalloproteinases (MMPs) start prote-
olytic degradation and pericytes are released from the 
basement membrane; ECs lose their junctions, allow-
ing vessels to dilate. VEGF acts at this point by in-
creasing the permeability of the EC layer, and plasma 
protein flows out establishing an ECM scaffold. Fol-
lowing integrin signaling, ECs migrate onto this ECM 
surface.  Angiogenic  mediators  of  the  ECM  such  as 
VEGF and fibroblast growth factor (FGF) are released 
by  proteinases.  These  factors  are  implicated  in  the 
constitution of the ECM as an appropriate angiogenic 
environment.  After  these  steps,  a  cell  is  selected  to 
lead vessel enlargement. VEGF gradient, regulated by 
soluble and  matrix bound isoforms,  makes tip cells 
upregulate delta-like ligand 4 (DLL4) expression, ac-
tivating NOTCH in stalk cells, then downregulating Theranostics 2012, 2(6) 
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VEGF receptors. As a consequence, stalk cells are less 
responsive to VEGF, helping the tip cells to take the 
lead. Tip cells respond to stimuli and move towards 
the angiogenic signal. Stalk cells, on the other hand, 
elongate the stalk by division and establish the vessel 
lumen [14].  
The complexity of this vasculogenic process has 
not  always  been  as  clear  as  it  is  now,  but  the  im-
portance of VEGF in the neovascularization process 
has been evident since it was first discovered. In the 
last  two  decades,  research  to  find  a  VEGF-based 
therapy to treat tissues damaged due to hypoxia has 
concluded in various clinical trials. In the next section, 
an  overview  of  the  clinical  trials  performed  in  the 
context of cardiovascular repair will be discussed.  
Clinical trials with VEGF: results and conclu-
sions  
The  results  of  small  phase  I  trials  using  intra-
coronary and intravenous infusions of VEGF in pa-
tients with coronary artery disease were encouraging 
[16-18].  For  example,  Hendel  et al.[17]  conducted  a 
study with 14 patients who underwent exercise and 
myocardial perfusion measurements before as well as 
30 and 60 days after VEGF administration. Although 
it was not designed to demonstrate VEGF efficacy, the 
study showed a significant improvement in exercise 
capacity without any safety issues. Also, the resting 
nuclear myocardial perfusion scans indicated a VEGF 
treatment effect. In another small study, a dose esca-
lation trial was designed to determine the safety and 
tolerability  of  intracoronary  VEGF  infusions  in  15 
patients  with  underperfused  myocardium.  As  a  re-
sult, myocardial perfusion imaging was improved in 7 
out of 14 patients at 60 days and all 7 patients with 
follow-up angiograms had improvements in the col-
lateral density score. This study also established that 
VEGF  can  safely  and  tolerably  be  administered  to 
humans  by  intracoronary  infusion  for  up  to  20 
minutes at 0.050 µg/kg/min [19]. In a study employ-
ing  intravenous  administration  of  VEGF  in  28  pa-
tients, the authors reported evidence of improvement 
in rest myocardial perfusion and in collateral density 
[16]. In spite of the promising results of these small 
phase  I  trials,  a  randomized,  double-blind,  place-
bo-controlled phase II trial failed to show differences 
between  the  VEGF  and  placebo  groups.  The  VIVA 
(Vascular  endothelial  growth  factor  in  Ischemia  for 
Vascular Angiogenesis) study compared two doses of 
VEGF to placebo in 178 patients with coronary artery 
disease. A single intracoronary infusion followed by 
three separate intravenous infusions was given. De-
spite  the  safety  and  tolerability,  the  administration 
regimes revealed that VEGF offered no improvement 
beyond placebo by day 60, although high-dose VEGF 
resulted in better improvement in angina and favora-
ble trends in exercise treadmill test time and angina 
frequency, by day 120 [20].  
The  results  of  myocardial  clinical  trials  using 
VEGF  delivery  have  generally  been  disappointing 
and  the  studies  have  failed  to  consistently  demon-
strate improvements in treated patients as compared 
with placebo. Many of these trials relied on an intra-
venous infusion or intracoronary delivery of the re-
combinant protein. It is noteworthy that VEGF is not 
effective  when  delivered  intravenously  [21].  There-
fore,  these  negative  results  have  been  attributed,  at 
least partially, to the short-lived effect and high in-
stability of the protein when injected as a bolus. In-
travenous  administration  of  VEGF  is  limited  by  its 
short  in vivo half life (~30 min) and  overall dose  is 
limited  by  off-target  site  toxicity  issues  [18].  In  the 
case  of  myocardial  ischemia,  the  amount  of  VEGF 
localized  in  the  ischemic  region  after  systemic  ad-
ministration is minimal and does not persist for more 
than 1 day [22]. Based on these issues, some unusual 
characteristics of the VIVA trial make interpretation of 
therapeutic  efficacy  of  VEGF  somewhat  difficult;  in 
particular, suboptimal dose or route of administration 
and uncontrolled delivery method of VEGF. Perhaps 
the most striking contribution of the VIVA trial was to 
consider that more preclinical data were needed with 
regard to the time course of angiogenesis and the op-
timal dose and route of administration to induce ef-
fective VEGF therapy in the myocardium. Also, given 
that the low recovery in the myocardium of the ad-
ministered VEGF might be another important cause of 
the missing clinical effect, local and sustained VEGF 
delivery by controlled release approaches in the heart 
tissue  might  be  a  better  strategy  to  achieve  higher 
efficacy  in  VEGF-based  therapy  for  myocardial  is-
chemia. Table 1  summarizes the  main clinical  trials 
using VEGF recombinant protein for cardiac repair. 
DELIVERY SYSTEMS  
Protein delivery systems 
When administering drugs to an organism, the 
goal is to reach the appropriate dose at the site of ac-
tion for the necessary period of time, so that the drug 
acts in its optimal condition, with the minimum ad-
verse  effects.  Drug  delivery  systems  (DDS)  are  de-
signed taking into account the specificities of the drug 
to be administered, the organism in which it is ad-
ministered and the disease being treated. Depending 
on these conditions, release profiles are designed and 
materials  and  device  architecture  are  chosen.  Even 
though the concept of drug delivery is relatively old, Theranostics 2012, 2(6) 
 
http://www.thno.org 
544 
its  application  to  biomolecules,  such  as  proteins, 
hormones,  antibodies  or  genes,  has  been  explored 
only in the last 15-20 years.  
 
Table 1. Clinical trials using VEGF recombinant proteins 
for cardiac repair. 
Route  Trial  n  Outcomes  Reference 
Intracoronary  Phase 
I 
14  Some improvement in perfu-
sion in patients treated with 
low-dose VEGF; five of six 
patients had perfusion im-
provement at rest and stress 
at higher doses 
[17] 
Intracoronary  Phase 
I 
15  Dose screening study; well 
tolerated up to 0.05 
mg/kg/min; myocardial 
perfusion imaging was im-
proved in 7 out of 14 patients 
at 60 days 
[18] 
Intravenous  Phase 
I 
28  An increase in exercise ca-
pacity was reported without 
any safety issues 
[16] 
Intracoronary/ 
intravenous 
Phase 
II 
178 VIVA study; safe and well 
tolerated; no improvement 
beyond placebo in all meas-
urements by day 60. By day 
120, high-dose VEGF result-
ed in significant improve-
ment in angina; no im-
provements in myocardial 
perfusion 
[20] 
 
As  scientists  make  progress  in  their  under-
standing  of  the  mechanisms  of  disease,  there  is  in-
creasing  awareness  that  protein  delivery  is  a  very 
attractive approach in many diseases. In our context, 
as clinical trials have highlighted, promoting angio-
genesis  via  growth  factors  (GFs)  or  cytokines  de-
mands the use of a DDS that preserves their proper-
ties and prolongs their short half life [23]. Proteins are 
labile systems with primary, secondary, tertiary and 
quaternary structures. Primary structure relates to the 
amino acid sequence, whereas higher structures refer 
to protein fold. Chemical instability is due to modifi-
cation at the first level, such as deamidation, oxida-
tion, beta elimination, incorrect disulfide formation or 
racemization. Physical instability refers to secondary, 
tertiary  and  quaternary  structure,  with  phenomena 
like denaturation, aggregation, precipitation and sur-
face adsorption. All these instability issues result in 
the short half life of VEGF when administered directly 
in the tissue. Incorporating VEGF in an adequate car-
rier serves to protect it until it is released from the 
device. However, incorporating VEGF, and any pro-
tein, in an adequate carrier poses unique difficulties 
due to physical and chemical instability. Temperature, 
pH, pressure, the presence of metal ions and dena-
turing agents like surfactants need to be tightly con-
trolled  during  the  manufacturing  process  to  avoid 
chemical instability.  
The  first  marketed  protein  included  in  a  DDS 
was  the  luteinizing  hormone  releasing  hormone 
(LHRH), which was commercialized by Astra Zeneca 
as Zoladex, with FDA approval in 1989 for the treat-
ment of prostate cancer. It was a 1.5 mm sized subcu-
taneous  implant  prepared  with  the  copolymer  pol-
ylactide-co-glycolide  (PLGA).  Nowadays  other  pro-
tein formulations have come on the market: long re-
lease octreotide (Octreotide® LAR®, Novartis Phar-
maceuticals), human growth hormone (Nutropin de-
pot®,  Genentech),  adenosin  deaminase  (Adagen®, 
Enzon),  L-asparaginase  (Oncaspar®,  Enzon),  Inter-
feron-α2 (Pegasys®, Roche) as examples. 
VEGF delivery systems in cardiac repair 
To  achieve  sustained  presence  of  VEGF  in  the 
damaged  tissue,  both  gene  therapy  and  DDS  have 
been  designed.  However,  the  aim  of  this  review  is 
focused on the second option. Updated information 
about gene therapy in this field can be found in the 
bibliography [24-27]. 
Studies published in the last five years related to 
VEGF delivery systems and cardiovascular diseases 
have been reviewed. Those corresponding to the last 
two  years  are  summarized  in  Table  2.  During  this 
period  of  time,  two  systems  have  been  the  most 
widely  employed:  scaffolds  and  particulated  con-
structs, represented in Figure 1. 
Scaffolds 
Most authors propose the use of scaffolds as de-
livery  platforms.  In  general,  the  requirements  that 
scaffolds  must  fulfill  are  several  [28]:  adequate  3D 
architecture with the desired shape, volume and me-
chanical  strength;  highly  porous  structure  to  allow 
tissue  growth  and  diffusion  of  biomolecules;  bio-
compability; appropriate degradation rate; and good 
interface adherence so that proteins attach in a desired 
way  to  the  material.  Particularly,  basic  physical  re-
quirements for myocardial engineered constructs are 
robust yet flexible mechanical properties, contractile 
ability, and electrophysiological stability [28, 29]. The 
physical and biochemical  effects of scaffolds in car-
diovascular differentiation have been reviewed else-
where [30]. Moreover, a scaffold designed for protein 
delivery  needs  to  show  high  loading  capacity,  ho-
mogenous protein distribution, a protein binding af-
finity  that allows adequate protein release and,  im-
portantly,  ability  to  maintain  protein  stability  and 
bioactivity. Theranostics 2012, 2(6) 
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Figure 1. The main DDSs employed in recent years in the field of VEGF and cardiac repair are represented. In the particles (nano or 
microsized) VEGF can be included homogenously through the entire particle (A) or only in the core of the system (B), which affects the 
release profile. A wide variety of scaffolds has been designed. In a thermosensitive injectable hydrogel (C) at temperatures under 37 ºC the 
blend of the vehicle and the VEGF remains liquid, but when it is injected and reaches the body temperature the mixture solidifies and VEGF 
is entrapped within the gel matrix (D). By electrospinning fibrous scaffolds are built up (E) whereas porous scaffolds (F) can be formed by 
solvent casting and particulate leaching method. 
 
Table 2. Summary of VEGF delivery and cardiac repair in the last 2 years. 
DDS  COMPOSITION  ANGIO
GENIC 
FACTO
R/S 
PREPARATION 
METHOD 
ANGIOGNENIC 
EFFICACY 
ASSAY 
AUTHOR'S CONCLUSION  REF. 
S
C
A
F
F
O
L
D
 
surface cross-
linked Heparin 
 
polycaprolactone  
VEGF  Solvent casting and 
particulate leaching 
method 
Subcutaneous 
implant model in 
mice 
Modification of the scaffold with 
heparin improves VEGF efficacy 
[37] 
hollow-fiber 
membrane 
cellulose acetate  VEGF & 
S1P 
Double injection 
extrusion/ precipi-
tation method 
Subcutaneous 
implant model in 
mice 
System capable of exploring sequen-
tial delivery of angiogenic factors.  
Sequential delivery of VEGF followed 
by S1P resulted in recruitment of 
more ECs and higher maturation 
index 
[43] 
biomimetic hy-
drogel (adhesion 
peptide se-
quence RGDS) 
PEG diacrylate   VEGF  Photopolymeriza-
tion 
In vitro (HUVECs 
and hMECs) 
The system promotes EC prolifera-
tion, migration and viability mainte-
nance 
[44] 
patch with co-
valently immo-
bilized VEGF 
collagen  VEGF  Commercial scaffold  Right ventricular  
free wall resection 
and replacement 
with the scaffold 
Collagen scaffold with covalently 
immobilized VEGF improved tissue 
formation 
[32] 
hydrogel with 
surface cross-
linked Heparin 
star-PEG  VEGF & 
FGF-2 
Cross linking  In vitro (HUVECs) 
and Chicken cho-
rioallantoin mem-
brane angiogéne-
sis assay 
Angiogenic activity superior to the 
administration of single factors 
[45, 
46] 
hydrogel  alginate  VEGF  Cross linking  Hindlimb ische-
mia in mice 
   [47] 
covalently im-
mobilized fac-
tors 
collagen  VEGF & 
Ang-1 
Commercial scaffold  Chicken 
chorioallantoin 
membrane 
angiogenesis assay 
Scaffolds with co-immobilized VEGF 
and Ang-1 further improved angio-
genesis as compared to inde-
pendently immobilized VEGF or 
Ang-1 
[31] 
composite  
scaffold 
Poly(ether)uretha
ne-polydimethylsi
VEGF & 
bFGF 
Spray-phase  
inversion method 
Subcutaneous 
implant and uni-
Incorporation of VEGF, bFGF and 
heparin in the composite scaffold 
[38] Theranostics 2012, 2(6) 
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loxane 
-fibrin 
lateral hind limb 
ischemia model in 
rat 
enhances angiogenesis 
temperature 
sensitive  in-
jectable hydro-
gel 
PVL-b-PEG-b-PVL  VEGF  Metal-free cationic  
method 
Myocardial infarc-
tion rat model 
(coronary artery 
ligation) 
The system preserved ventricular  
function by stabilizing the infarct and 
reducing angiogenesis 
[41] 
fibrous mem-
branes 
Dextran/PLGA  VEGF  Coaxial electrospin-
ning 
In vitro  The system positively promotes cell 
proliferation  
[48] 
dual layered 
scaffold com-
bined with an 
osmotic release 
mechanism 
Poly(trimethylene 
carbonate) 
VEGF & 
HGF 
Cross linking  In vitro (HAECs)  System able to release combined GFs 
at similar rates, and at controllable 
sequences 
[49] 
P
A
R
T
I
C
L
E
S
 
NPs  Hyaluronic ac-
id/chitosan 
VEGF & 
PDGF-B
B 
Ionic gelification 
technique 
-  NPs entrap efficiently both factors. 
PDGF-BB is released in a sustained 
manner over 1 week and VEGF 
within the first 24 hours. 
[50] 
PLGA/heparin/fi
brin 
VEGF  Spontaneous emul-
sion solvent diffu-
sion method 
Rabbit ischemic 
hind limb 
The system strongly increases the in 
vivo therapeutic angiogenic effects of 
VEGF 
[51] 
PLGA  VEGF  Modification of the 
double emulsion 
method 
Hindlimb ische-
mia in mice 
Feasibility of the system  
to produce a more viogorous revas-
cularization when compared with 
free VEGF administration 
[52] 
MPs  PLGA  VEGF  Double emul-
sion/solvent evap-
oration method 
In vitro (HUVECs)  The system allows VEGF encapsula-
tion and bioactive protein release up 
to 21 days 
[53] 
PLGA  VEGF  Double emul-
sion/solvent evap-
oration method 
Myocardial infarc-
tion rat model 
(coronary artery 
ligation) 
   [54] 
Collagen  VEGF  Cross linking  In vitro (HUVECs)  The system allows VEGF encapsula-
tion and bioactive protein release up 
to 4 weeks 
[55] 
P
A
R
T
I
C
L
E
S
-
S
C
A
F
F
O
L
D
 
MPs 
MPs-Scaffold 
PLGA 
(MPs)PLGA-N-me
thyl pyrrolidone 
(scaffold) 
VEGF  MPs: spray dry 
Scaffold: gelification 
Murine model of 
peripheral angio-
genesis 
Both formulations provide a method 
to incite neovascularization from a 
single injection 
[56] 
NPs 
Scaffolds (hy-
drogel or poly-
meric) 
NPs-Scaffold 
(hydrogel or 
polymeric) 
NPs: Dex-
tran-sulfate/chitos
an 
Scaffold: Mat-
rigel® or PLGA 
VEGF  NPs: complex for-
mation and coacer-
vation 
Scaffold: gas foam-
ing/particulate 
leaching method 
(Matrigel®: com-
mercially obtained) 
Subcutaneous 
injection 
(NPs-Matrigel®) 
NPs-PLGA scaf-
folds implanted 
into the intraperi-
oneal fat pad of 
mice 
Angiogenesis was clearly improved 
by VEGF encapsulation and further 
incorporation into implants, com-
pared to direct VEGF incorporation 
into implants 
[57] 
MPs-Scaffold  
co-administered 
with ECs 
Alginate MPs 
colla-
gen/fibronectin 
gel 
VEGF & 
MCP-1 
Cross linking  Subcutaneous 
implant  model in 
mice 
Delivery of multiple therapeutic pro-
teins to enhance the efficacy of 
cell-based vascularization 
[58] 
O
T
H
E
R
 
Polymeric  
injectable carrier 
Poly(trimethylene 
carbonate) 
VEGF  -  Subcutaneous 
injection in rat 
The approach has potential for 
providing effective, local, bioactive 
growth factor delivery.  
[59] 
Collagen patch-
es 
Collagen  VEGF  Collagen binding 
domain is fused to 
VEGF 
Myocardial im-
plantation 
Patches improve left ventricular car-
diac function and increase the vascu-
lar density 
[60] 
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These devices can be constructed with natural or 
synthetic  biomaterials.  In  the  past  the  use  of 
non-degradable  constructs  involved  a  second  inter-
vention to extract these. Nowadays the use of biode-
gradable devices is almost presupposed. Components 
found  in  the  ECM  are  preferably  from  within  the 
range of natural materials: collagen, fibrinogen, hya-
luronic acid (HA), chitosan, alginate, etc. The use of 
these  natural  scaffolds  has  increased  during  recent 
years and companies have already put them on the 
market. In the last two years, Radisic et al have pub-
lished two papers in which they immobilize VEGF in 
a commercial ultrafoam [31, 32], demonstrating that 
the system has suitable mechanical properties for po-
tential use in repairing heart defects and that it im-
proves angiogenesis both in vitro [31] and in vivo, in a 
rat heart injury model [32]. Because of their natural 
origin, most of these components are biocompatible, 
bioactive and tend to show similar mechanical prop-
erties to the native tissue. However, synthetic materi-
als  have  been  developed  with  optimal  qualities  for 
tissue regeneration. Elastomeric scaffolds such as poly 
(glycolic acid) (PGA) and poly (lactid acid) (PLA), as 
well as their copolymer PLGA, have been successfully 
applied [33-35]. Like natural materials, polyesters are 
biocompatible and biodegradable, and by controlling 
polymerization  it  is  possible  to  modulate  their  me-
chanical  properties.  In  fact,  PLGA  has  already  re-
ceived FDA approval for its use in drug delivery [36] 
Also  polyanhydrides  and  other  polyesters,  such  as 
polycaprolactone (PCL) [37], have been shown to be 
possible alternatives as VEGF carriers. In recent years, 
different materials have been combined to modulate 
the mechanical and biological properties of the scaf-
fold.  To  give  an  example,  fibrin-based  biomaterials 
have been found to stimulate and support the growth 
of  new  blood  vessels,  but  their  poor  mechanical 
properties  have  encouraged  researchers  to  combine 
them with synthetic materials. Losi et al [38] have ob-
tained composite scaffolds made of a synthetic layer 
of  poly(ether)urethane- 
polydimethylsiloxane,  contributing  to  mechanical 
resistance, and a fibrin layer that acts as a GF delivery 
carrier.  
Numerous  preparation  methods  have  been  re-
ported  for  manufacturing  3D  porous  scaffolds, 
namely fiber bonding, emulsion freeze drying, solvent 
casting/particulate leaching [37], high pressure pro-
cessing, gas foaming/particulate leaching, thermally 
induced  phase  separation,  electrospinning  [39]  and 
rapid  prototyping  (reviewed  in  [40]).  Recently,  in-
jectable  biomaterials  that  form  scaffold  in situ have 
been  used.  These  can  be  administered  parenterally, 
but also locally, with the advantage that the scaffold 
acquires the shape of the tissue defect and surgery is 
avoided.  Recently,  Wu  et  al  [41],  prepared  a 
VEGF-conjugated  injectable  hydrogel  that  was  in-
tramyocardially injected into Sprague Dawley rat in-
farcted  hearts,  preserving  ventricular  function  after 
myocardial  ischemia  by  stabilizing  the  infarct  and 
inducing  angiogenesis.  The  gel  was  composed  of  a 
temperature  sensitive  aliphatic  polyester  (poly 
(δ-valerolactone)-block-ply  (ethylene  gly-
col)-block-poly  (δ-valerolactone)).  This  polymer  is 
called thermosensitive since it dissolves in water at 
room temperature, but gels at 37 ºC (see Fig. 1C). This 
property makes this kind of material especially inter-
esting.  
The route of administration to reach the infarct-
ed heart still remains challenging (see Figure 2) [42]. 
When implanting a scaffold in the heart, surgery is 
necessary,  with  the  consequent  inconvenience  and 
risks for the patient. The scaffold in that case needs to 
be placed covering the infarcted zone, or surrounding 
it, so that GFs are released towards the cells acting in 
the repair process and are responsive to VEGF (Fig. 
1A).  If  an  injectable  gel  is  used,  surgery  may  be 
avoided, since it can be directly injected into the heart 
without surgical intervention (Fig. 1C). 
To optimize scaffold effectiveness, it can be sur-
face  modified.  Collagen  and  gelatin  are  known  to 
modulate  adhesive  properties.  The  attachment  of  a 
cell  adhesive  peptide  on  the  surface  improves  lig-
and-receptor interaction, as well as cell adhesion. In a 
recent article, Porter et al [44] propose the preparation 
of a biomimetic hydrogel by including an adhesion 
peptide sequence derived from fibronectin (RGDS), in 
a  VEGF  covalently  incorporated  PEG  hydrogel,  to 
enhance cell adhesion. However, in this study only in 
vitro assays were performed. Hyaluronic acid (HA) is 
a  substance  present  in  the  ECM  that  interacts  with 
CD4 receptor, promoting wound healing, making its 
use  attractive.  Heparin  modification  has  also  been 
extensively studied for the release of GFs. Heparin is a 
highly sulfated glycosaminoglycan in the ECM, and is 
known for its specific interactions with various angi-
ogenic GFs [61, 62]. A wide variety of scaffolds in-
cluding  nanofibers,  prepared  from  collagen,  fibrin, 
chitosan, alginate, PLA and PLGA, have been immo-
bilized with heparin to achieve sustained release of 
GFs [40, 63]. Based on this, Zieris et al [37, 45] prepared 
a biohybrid hydrogel with star-shaped PEG and car-
bodiimide/N-hydroxysulfosuccinimiede-activated 
heparin,  obtaining  appropriate  VEGF  binding  and 
release, with good in vitro results (included in Table 
2). On the other hand, Singh et al [37] demonstrated an 
enhanced VEGF angiogenic effect, in a subcutaneous 
implant  model,  when  a  PCL  scaffold  was  surface Theranostics 2012, 2(6) 
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modified with heparin. 
 
 
 
Figure  2. Depending on the VEGF carrier different routes of 
administration can be chosen. Solid scaffolds need to be attached 
to the heart, frequently covering the infarcted area (A). Particles 
can be injected in the desired zone intracoronarily using a catheter 
(B)  or  by  direct  injection  (C).  Injectable  scaffolds  can  also  be 
implanted using this route. 
 
Nano/Microparticles 
Among  the  particulated  delivery  systems  MPs 
(>1 µm and < 1,000 µm sized) and NPs (< 1 µm sized) 
have been used for VEGF delivery. Microsized parti-
cles are not readily internalized by the cells, but they 
have the potential to provide sustained release kinet-
ics after implantation. In addition, MP diffusion from 
the implantation site is infrequent, which avoids un-
desired  effects  in  other  tissues.  Thus,  MPs  provide 
control over the release rate and dose, yielding de-
sirable concentrations for a period of time [64]. On the 
other hand, NPs can penetrate through capillaries into 
the cell machinery. Therefore, the pro-angiogenic po-
tential of GFs in NPs or MPs in the tissue is not nec-
essary  equivalent.  In  relation  to  drug  distribution 
within  the  particle,  we  can  distinguish  between 
nano/microcapsules and nano/microspheres (see Fig. 
1A and 1B). A clear advantage of these DDS, when 
compared with scaffolds, is the route of administra-
tion.  As  it  has  been  mentioned  before,  most  of  the 
scaffolds  need  to  be  implanted  through  a  surgical 
intervention. In the case of the particles, they can be 
injected  directly  into  the  myocardium  without  sur-
gery.  Frequently,  several  injections  are  performed 
around  the  infarcted  area,  in  the  confluence  of  the 
healthy and the damaged tissue (see Fig. 2C). Another 
non-invasive route for these DDS is the intracoronary 
route via a catheter (see Fig. 2B). 
To  prepare  these  DDSs,  numerous  strategies 
have  been  employed,  among  others,  solvent  extrac-
tion/evaporation, spray drying and phase separation 
method  [65].  Spray  drying  is  associated  with  low 
process efficacy and protein denaturing due to dehy-
dration [66]. The phase separation method is medi-
ated by a solvent and coacervating agent that can re-
act with the protein and disrupt the secondary struc-
ture. Moreover, this is a process that is not well suited 
to  producing  particles  in  the  low  micrometer  size 
range  [67].  The  solvent  extraction/evaporation 
method is thus thought to be, to date, the most ap-
propriate. Two different modifications of this proce-
dure are the single emulsion and the double emulsion 
solvent  evaporation  method.  In  the  first  one,  since 
proteins are hydrophobic molecules, low encapsula-
tion efficiency (EE) values are obtained. EE is an im-
portant feature and can be defined as the capability of 
immobilizing most of the protein added during the 
process. In the single emulsion case, protein is incor-
porated in the external phase of the emulsion (o/w), 
whereas in the double emulsion the protein is local-
ized in the internal aqueous phase (w/o/w), dimin-
ishing  the  loss  of  the  molecule.  Nevertheless,  this 
method presents some drawbacks, such as the need to 
reach  high  temperatures  or  to  employ  mechanical 
forces that can damage the protein. Systems to avoid 
elevated temperatures and stirring during the emul-
sion preparation have now been designed. An exam-
ple is the Total Recirculation One Machine System® 
(TROMS)  [68].  In  the  TROMS,  the  inner  aqueous 
phase  of  the  emulsion  is  injected  into  the  organic 
phase.  This  blend  is  forced  to  circulate  through  a 
closed  circuit  with  a  specified  inner  diameter  for  a 
period of time. Once the first emulsion is formed, it is 
injected into the external aqueous phase leading, after 
a period of time in circulation, to the constitution of 
the  double  emulsion  without  inflicting  too  much 
stress on the protein so that bioactivity is preserved. 
Employing TROMS we have been able to encapsulate 
VEGF and other proteins in PLGA microparticles with 
EE values over 80% while maintaining protein bioac-
tivity during the formulation process [54, 69]. On the 
other hand, the formation of aqueous/organic solvent 
interfaces  is  the  main  disadvantage  of  this  method. 
Also,  when  using  PLGA  copolymer,  hydrophobic 
interactions  between  the  protein  and  PLGA  are  re-
sponsible for protein aggregation and denaturing. To 
minimize these effects, addition of human serum al-
bumin  (HSA)  or  surfactants  such  as  poly  ethylene 
glycol (PEG), helps to protect the protein by prevent-
ing  hydrophobic  contacts  [70].  Another  important 
factor to take into account is pH modification. When 
PLGA degrades, pH decreases due to the presence of Theranostics 2012, 2(6) 
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glycolic and lactic acid [71], and this is associated with 
a loss of bioactivity as a consequence of protein ag-
gregation and chemical degradation. It may also be 
possible  that  PLGA  degradation  products  and  pro-
teins react, leading, for example, to protein acetylation 
[71].  Therefore  approaches  to  reduce  acid-induced 
damage have been discussed, such as incorporating 
Mg(OH)2 in the formulation [72]. 
PLGA  particles  with  VEGF  have  been  studied 
extensively for ischemia tissue repair [52-54] and they 
appear to be a promising strategy. Guldberg et al [52] 
demonstrated a vigorous revascularization response 
when  treating  a  hindlimb  ischemia  model  in  mice 
with VEGF-NPs, which was greater than the response 
obtained after 5 μg VEGF, 2.5 μg VEGF, and saline 
treatment. VEGF-MPs were also prepared by Baysal et 
al [53] to face therapeutic angiogenesis. In this study, 
MPs  succeeded  in  promoting  HUVEC  proliferation 
and  migration.  Our  group  developed  VEGF  loaded 
PLGA MPs which, when intramyocardially injected in 
an infarcted heart rat model, improved vasculogene-
sis and tissue remodeling [54].  
Particles included in scaffolds 
More sophisticated systems can be prepared by 
incorporating protein loaded particles into scaffolds. 
These kinds of system present some features that can 
be of interest in some situations. Firstly, the release 
profile is modified (Fig. 3). In short, the burst effect is 
maintained while the sustained release of the protein 
is prolonged  [64]. However, possibilities are unlim-
ited, since the GF can be included both in the particles 
and in the scaffold, or just inside the particles. Also, 
GFs can be covalently immobilized in the carriers or 
non-covalently, leading to different delivery. Moreo-
ver, the scaffold architecture can modulate different 
release profiles, depending on whether it is a multi-
layered system or a core-shell system. All these alter-
natives, and others, have been recently reviewed by 
Chen et al [64]. 
 
 
 
 
Figure 3. Simplification of how VEGF release profile can be modified when included in particles or in particles embedded in scaffolds.  
 
An  elegant  construct  has  been  described  by 
Chung et al [51]. They compare the angiogenesis po-
tential of VEGF when included in a fibrin gel or when 
included  in  a  heparin-functionalized  nanoparticle 
incorporated in the same fibrin gel. In the first case, 
almost 100% of VEGF was released within the first 3 
days,  whereas  sustained  release  of  the  protein  was 
observed  for  more  than  30  days  in  the  second  ap-
proach,  resulting  in  an  enhanced  angiogenic  effect. 
Recently,  des  Rieux  et  al  [57]  investigated  whether 
angiogenesis is enhanced when administering VEGF 
that  is  freely  incorporated  in  two  types  of  matrices 
(Matrigel®  or  PLGA)  or  when  VEGF  is  previously 
encapsulated  in  dextran-chitosan  nanoparticles.  The 
results  lead  these  authors  to  conclude  that  a  more 
interesting approach could be to fill the PLGA scaf-
fold  pores  with  the  hydrogel,  both  systems  being 
loaded with VEGF nanoparticles, and thus combine 
three carrier systems.  
Combination of VEGF with other biomolecules 
When trying to regenerate heart tissue, the com-
bination  of  several  factors  (pro-angiogenic,  cardio-
protective  and  chemoattracting)  could  be  a  good 
strategy [73]. As described above, a hypoxic stimulus 
in  the  heart  activates  not  only  VEGF  and 
neo-vascularization,  but  complex  and  tightly  spa-
tio-temporally coordinated pathways,  involving dif-
ferent cells and inter-regulated factors. DDSs appear 
in this context not only as the way to prolong the short 
half life of all these biomolecules, but also as a suitable 
platform to mimic the optimum environment for the 
tissue to regenerate, by delivering various GFs in a 
different but controlled manner. Work in this field has 
increased  in  recent  years.  VEGF  has  been  incorpo-
rated into carriers together with other factors; the next 
step  is  to  prepare  systems  that  allow  a  dual  or  se-
quential delivery of factors with a tight dose control 
[46]. Recently Chapanian and Amsden [49] have been Theranostics 2012, 2(6) 
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able to create a system for the combined and sequen-
tial delivery of VEGF and hepatocyte growth factor. 
The construct is composed of trimethylene carbonate 
based  elastomers  and  is  combined  with  an  osmotic 
mechanism to release acid-sensitive GFs, preserving 
its bioavility. Another approach is the combination of 
VEGF with Angiopoietin-1, another GF implicated in 
vascular  stabilization  and  remodeling  [31].  These 
were covalently immobilized in collagen scaffolds and 
a  chicken  chorioallantoic  membrane  angiogenesis 
assay was performed to test the system. The results 
led  these  authors  to  conclude  that  scaffolds  with 
co-immobilized  VEGF  and  Ang1  further  improved 
angiogenesis, as compared to independently immobi-
lized VEGF or Ang1. Also, covalent immobilization of 
growth factors on the scaffolds yielded better results 
compared to simple addition of soluble growth fac-
tors  to  scaffolds  (Table  2).  Other  factors  combined 
with VEGF have been FGF-2 in PEG based hydrogels 
[45, 46], PDGF-BB in alginate hydrogels [74] and in 
HA/chitosan NPs [50], bFGF in a composite scaffold 
[38] and sphingosine 1-phosphate [43]. The work of 
Hao et al [74] is particularly worth mentioning. While 
the majority of the studies have just proved the ability 
of the system to incorporate GFs and to deliver them, 
in this case the system was applied to a myocardial 
infarction rat model, with the formation of more ma-
ture  vessels  and  improvement  of  cardiac  function 
when compared to delivery of single factors [17, 74]. 
Despite these results, it is still necessary to answer the 
question  as  to  which  the  appropriate  VEGF 
co-factor/s are and what the ideal release profile for 
each one is.  
Application of Drug delivery systems in the 
ischemic heart 
To sum up, it is possible to conclude that each 
delivery system has its own advantages and limita-
tions. As mentioned before, the administration route 
is a key point to take into account. Several methods of 
delivery  are  used  (Figure  2.)  depending  on  the  pa-
thology of the patient. In the case of chronic myocar-
dial ischemia, direct intramyocardial injection is pre-
ferred, since it allows delivery in the ischemic tissue 
with an occluded artery [75]. Direct intramyocardial 
injection  can  be  trans-epicardial,  trans-endocardial, 
and less frequently, trans-venous. The first is usually 
performed during open heart surgery, and due to the 
high risk, is not performed as a standalone procedure. 
Another context is an acute myocardial infarction, in 
which  intracoronary  injection  is  the  most  frequent 
method [76].  
On  balance,  solid  scaffolds  present  the  disad-
vantage  of  needing  to  be  implanted  in  the  heart, 
making  surgery  mandatory.  Solid  scaffolds  would 
therefore not be an adequate DDS to treat acute my-
ocardial ischemia, or for chronic myocardial ischemia 
when the patient requires open heart surgery.  
The administration route is not the only feature 
to be taken into account when choosing a DDS. For 
instance, scaffolds have the drawback of the admin-
istration route but they show the benefit of covering 
the total area of the infarct. In consequence, if they are 
built with materials able to reproduce the extracellu-
lar matrix, they can help the heart to overcome the 
consequences  of  the  negative  remodeling  [77].  Fur-
thermore, if the aim is to administer more than one 
factor  with  different  release  profiles,  the  scaffold 
elaboration process becomes more complicated, as it 
is necessary to include in it, for instance, particles that 
modify the release rate of one or more of the active 
molecules. 
On the other hand, use of particles makes all the 
administration  routes  possible.  It  is  also  easier  to 
combine different particles containing several factors, 
theoretically providing a more orchestrated signaling 
environment to the damage tissue.  
In relation to the possibility of preparing an en-
gineered construct including factors, DDS and cells, 
both scaffold and MPs are potentially useful, whereas 
the  reduced  area  of  NPs  does  not  provide  enough 
space to attach cells to their surface. Sustained release 
of the factors is also difficult to achieve when admin-
istering NPs, not to mention their greater likelihood of 
being removed from the tissue by phagocytic uptake.  
Most  of  the  published  studies  using  VEGF 
loaded in DDSs carried out limited in vivo studies, and 
just  a  few  of  them  have  applied  VEGF-DDS  in  the 
ischemic heart. Thus, it is still too soon to conclude 
which DDS is the most suitable to apply in cardiac 
repair. 
Therefore,  as  all  DDS  present  advantages  and 
disadvantages, combining them to prepare more so-
phisticated  constructs  could  make  it  possible  to  ex-
ploit the benefits of each one in order to give the op-
timal  signals  to  the  cardiac  tissue  that  needs  to  re-
generate. 
FUTURE DIRECTIONS: THE TISSUE 
ENGINEERING TRIAD 
As  the  same  time  as  the  number  of  papers  in 
which  GFs  and  DDSs  are  combined  has  increased, 
numerous researchers have focused on cell therapy to 
treat  cardiac  injury[42].  Just  as  DDSs  appear  in  the 
first  case  as  a  suitable  approach  for  prolonging  the 
permanence of GFs in the tissue, the cell engraftment 
approach may well be extended by including cells in 
scaffolds. So far, these scaffolds have progressed to Theranostics 2012, 2(6) 
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mimic the cell’s natural environment as far as possi-
ble,  aiding  in  its  survival  and  development.  In  this 
sense, the incorporation of factors in the scaffold helps 
not only to modulate cell life, but also acts in the tissue 
and improves its recovery. The combination of engi-
neered platforms, cells and GFs has been named the 
tissue engineering triad, and seems to be a promising 
tool in the field of cardiac repair. A considerable re-
search effort is now needed to establish the “winning 
combination”. 
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